Features of Cell-Mediated Immunity in Children with Congenital Ichthyosis and Their Role in the Pathogenetic Management ; Особенности клеточного иммунитета у детей с врожденным ихтиозом и их роль в стратегии патогенетической терапии заболевания

Authors: Karine O. Avetisyan, Nikolay N. Murashkin, Svetlana G. Makarova, Svetlana S. Petrichuk, Daria G. Kuptsova, К. О. Аветисян, Н. Н. Мурашкин, С. Г. Макарова, С. С. Петричук, Д. Г. Купцова

Contributors: Not specified, Отсутствует

Source: Current Pediatrics; Том 22, № 5 (2023); 415-424 ; Вопросы современной педиатрии; Том 22, № 5 (2023); 415-424 ; 1682-5535 ; 1682-5527

Subject Terms: регуляторные Т-клетки, children, epidermal barrier, cell-mediated immunity, activated T-helpers, Th17-lymphocytes, Treg-cells, дети, эпидермальный барьер, клеточный иммунитет, активированные T-хелперы, Th17-лимфоциты

File Description: application/pdf; application/msword

Relation: https://vsp.spr-journal.ru/jour/article/view/3303/1323; https://vsp.spr-journal.ru/jour/article/view/3303/1334; Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol. 2010;63(4):607–641. doi: https://doi.org/10.1016/j.jaad.2009.11.020; Richard G. Autosomal Recessive Congenital Ichthyosis. 2001 Jan 10 [Updated 2023 Apr 20]. In: GeneReviews® [Internet]. Adam MP, Mirzaa GM, Pagon RA, et al., eds. Seattle (WA): University of Washington, Seattle; 1993–2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1420. Accessed on October 19, 2023.; Мурашкин Н.Н., Аветисян К.О., Иванов Р.А., Макарова C.Г. Врожденный ихтиоз: клинико-генетические характеристики заболевания // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 362–377. — doi: https://doi.org/10.15690/vsp.v21i5.2459; Sun Q, Burgren NM, Cheraghlou S, et al. The Genomic and Phenotypic Landscape of Ichthyosis: An Analysis of 1000 Kindreds. JAMA Dermatol. 2022;158(1):16–25. doi: https://doi.org/10.1001/jamadermatol.2021.4242; Ихтиоз у детей: клинические рекомендации. — Союз педиатров России; 2016. — С. 6.; Lee AY. Molecular Mechanism of Epidermal Barrier Dysfunction as Primary Abnormalities. Int J Mol Sci. 2020;21(4):1194. doi: https://doi.org/10.3390/ijms21041194; Malik K, He H, Huynh TN, et al. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol. 2019;143(2):604–618. doi: https://doi.org/10.1016/j.jaci.2018.03.021; Кондратенко И.В., Бологов А.А. Первичные иммунодефициты: учебное пособие. — М.: ИндексМед Медиа; 2020. — С. 31.; Czarnowicki T, He H, Leonard A, et al. The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. J Invest Dermatol. 2018;138(10):2157–2167. doi: https://doi.org/10.1016/j.jid.2018.03.1523; Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152–165. doi: https://doi.org/10.1016/j.jaci.2016.07.019; Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol. 2019;180(2):272–281. doi: https://doi.org/10.1111/bjd.17203; Mazereeuw-Hautier J, Hernández-Martín A, O’Toole EA, et al. Management of congenital ichthyoses: European guidelines of care, part two. Br J Dermatol. 2019;180(3):484–495. doi: https://doi.org/10.1111/bjd.16882; Youssefian L, Vahidnezhad H, Saeidian AH, et al. Autosomal recessive congenital ichthyosis: Genomic landscape and phenotypic spectrum in a cohort of 125 consanguineous families. Hum Mutat. 2019;40(3):288–298. doi: https://doi.org/10.1002/humu.23695; Sabat R, Wolk K, Loyal L, et al. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359–377. doi: https://doi.org/10.1007/s00281-019-00742-7; Купцова Д.Г., Радыгина Т.В., Курбатова О.В. и др. Содержание субпопуляций CD4+T-клеток в прогнозе эффективности биологической терапии псориаза у детей // Медицинская иммунология. — 2023. — Т. 25. — № 5. — С. 1071–1078. — doi: https://doi.org/10.15789/1563-0625-COC-2704; Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015;4(5):858–873. doi: https://doi.org/10.3390/jcm4050858; Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В. и др. Новая эра в лечении атопического дерматита: результаты длительного применения дупилумаба // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 390–395. — doi: https://doi.org/10.15690/vsp.v20i5.2312; Купцова Д.Г., Петричук С.В., Мурашкин Н.Н. и др. Ранние предикторы эффективности биологической терапии псориаза у детей // Аллергология и иммунология в педиатрии. 2023. — № 1. — С. 49–52. — doi: https://doi.org/10.53529/2500-11752023-1-49-52; Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18(3):156–169. doi: https://doi.org/10.2310/7750.2013.13125; Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: https://doi.org/10.1016/j.jaad.2018.11.057; Wollenberg A, Thomsen SF, Lacour JP, et al. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi: https://doi.org/10.1016/j.waojou.2021.100519; Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelinesdupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: https://doi.org/10.1111/all.14690; Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi: https://doi.org/10.1111/all.13954; Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi: https://doi.org/10.1016/s0140-6736(21)00184-7; Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–1147. doi: https://doi.org/10.1084/jem.20082242; Reche PA, Soumelis V, Gorman DM, et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol. 2001;167(1):336–343. doi: https://doi.org/10.4049/jimmunol.167.1.336; Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131(9):1947–1950. doi: https://doi.org/10.1038/jid.2011.124; Кондратенко И.В., Бологов А.А. Первичные иммунодефициты: учебное пособие. — М.: ИндексМед Медиа; 2020. — С. 117–120.; Eränkö E, Ilander M, Tuomiranta M, et al. Immune cell phenotype and functional defects in Netherton syndrome. Orphanet J Rare Dis. 2018;13(1):213. doi: https://doi.org/10.1186/s13023-018-0956-6; Hannula-Jouppi K, Laasanen SL, Ilander M, et al. Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation. JAMA Dermatol. 2016;152(4):435–442. doi: https://doi.org/10.1001/jamadermatol.2015.5827; Paller AS. Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses. J Invest Dermatol. 2019;139(3): 535–540. doi: https://doi.org/10.1016/j.jid.2018.08.027; Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol. 2018;78(3):498–505.e2. doi: https://doi.org/10.1016/j.jaad.2017.10.026; Luchsinger I, Knöpfel N, Theiler M, et al. Secukinumab Therapy for Netherton Syndrome. JAMA Dermatol. 2020;156(8):907–911. doi: https://doi.org/10.1001/jamadermatol.2020.1019; Yogarajah J, Gouveia C, Iype J, et al. Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiencyrelated ichthyosis in a child. Skin Health Dis. 2021;1(2):e25. doi: https://doi.org/10.1002/ski2.25

Availability: https://vsp.spr-journal.ru/jour/article/view/3303
https://doi.org/10.15690/vsp.v22i5.2645

Modern Treatment Options for Epidermal Dysfunction at Atopic Dermatitis ; Современные возможности коррекции эпидермальной дисфункции при атопическом дерматите

Authors: Eduard T. Ambarchyan, Anastasiya D. Kuzminova, Vladislav V. Ivanchikov, Э. Т. Амбарчян, А. Д. Кузьминова, В. В. Иванчиков

Contributors: Not declared, Отсутствует

Source: Current Pediatrics; Том 22, № 5 (2023); 382-386 ; Вопросы современной педиатрии; Том 22, № 5 (2023); 382-386 ; 1682-5535 ; 1682-5527

Subject Terms: эмоленты, filaggrin, filagrinol, epidermal barrier, emollient, филаггрин, филагринол, эпидермальный барьер

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3298/1318; Rauer L, Reiger M, Bhattacharyya M, et al. Skin microbiome and its association with host cofactors in determining atopic dermatitis severity. J Eur Acad Dermatol Venereol. 2023;37(4):772–782. doi: https://doi.org/10.1111/jdv.18776; Boguniewicz M, Alexis AF, Beck LA, et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–1531. doi: https://doi.org/10.1016/j.jaip.2017.08.005; Taylor K, Swan DJ, Affleck A, et al. Translational Research Network in Dermatology and the U.K. Dermatology Clinical Trials Network. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017;176(6):1617–1623. doi: https://doi.org/10.1111/bjd.15235; Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi: https://doi.org/10.1016/j.anai.2020.12.020; Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651. doi: https://doi.org/10.1016/j.jaci.2016.07.013; Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532.e7. doi: https://doi.org/10.1016/j.jaad.2018.05.1241; Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–1503. doi: https://doi.org/10.1172/JCI124611; Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/s0140-6736(20)31286-1; Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840–1852. doi: https://doi.org/10.1016/j.jaip.2020.02.022; Beck LA, Cork MJ, Amagai M, et al. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID Innov. 2022;2(5):100131. doi: https://doi.org/10.1016/j.xjidi.2022.100131; Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023): 1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-X; Barker JN, Palmer CN, Zhao Y, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127(3):564–567. doi: https://doi.org/10.1038/sj.jid.5700587; Saunders SP, Moran T, Floudas A, et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol. 2016;137(2):482–491. doi: https://doi.org/10.1016/j.jaci.2015.06.045; Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: https://doi.org/10.1016/j.jaci.2008.01.022; Kim BE, Leung DYM. Significance of Skin Barrier Dysfunction in Atopic Dermatitis. Allergy Asthma Immunol Res. 2018;10(3): 207–215. doi: https://doi.org/10.4168/aair.2018.10.3.207; Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138:350–358.e1. doi: https://doi.org/10.1016/j.jaci.2016.06.002; Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118–S127. doi: https://doi.org/10.1016/j.jaci.2003.09.033; Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: https://doi.org/10.1016/j.jaci.2017.04.004; Grobe W, Bieber T, Novak N. Pathophysiology of atopic dermatitis. J Dtsch Dermatol Ges. 2019;17(4):433–440. doi: https://doi.org/10.1111/ddg.13819; Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol. 2020; 48(2):130–139. doi: https://doi.org/10.1111/1346-8138.15664; Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020; 21(8):2867. doi: https://doi.org/10.3390/ijms21082867; Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: A systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065; Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: The skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi: https://doi.org/10.1111/bjd.16934; Ishikawa J, Narita H, Kondo N, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010;130(10): 2511–2514. doi: https://doi.org/10.1038/jid.2010.161; Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433. doi: https://doi.org/10.1007/s11882-014-0433-9; Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: Beyond filaggrin. Bras Dermatol. 2016;91(4):472–478. doi: https://doi.org/10.1590/abd1806-4841.20164412; Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013; 131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566; Мурашкин Н.Н., Иванов Р.А., Амбарчян Э.Т. и др. Филаггрин и атопический дерматит: клинико-патогенетические параллели и возможности терапевтической коррекции // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 435–440. — doi: https://doi.org/10.15690/vsp.v20i5.2320; Moosbrugger-Martinz V, Leprince C, Méchin M-C, et al. Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int J Mol Sci. 2022;23(10):5318. doi: https://doi.org/10.3390/ijms23105318; On HR, Lee SE, Kim SE, et al. Filaggrin Mutation in Korean Patients with Atopic Dermatitis. Yonsei Med J. 2017;58(2): 395–400. doi: https://doi.org/10.3349/ymj.2017.58.2.395; Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1–9. doi: https://doi.org/10.2332/allergolint.10-RAI-0270; Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. doi: https://doi.org/10.11613/BM.2019.020501; Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762. doi: https://doi.org/10.1038/jid.2011.393; Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta. 1982;719(1):110–117. doi: https://doi.org/10.1016/0304-4165(82)90314-2; Hoste E, Kemperman P, Devos M, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233–2241. doi: https://doi.org/10.1038/jid.2011.153; Kamata Y, Taniguchi A, Yamamoto M, et al. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem. 2009;284(19):12829–12836. doi: https://doi.org/10.1074/jbc.M807908200; Круглова Л.С., Переверзина Н.О. Филаггрин: от истории открытия до применения модуляторов филаггрина в клинической практике (обзор литературы) // Медицинский алфавит. — 2021. — № 27. — С. 8–12. — doi: https://doi.org/10.33667/2078-5631-2021-27-8-12; Мурашкин Н.Н., Епишев Р.В., Иванов Р.А. и др. Инновации в терапевтической коррекции микробиома кожи при атопическом дерматите в детском возрасте // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 352–361. — doi: https://doi.org/10.15690/vsp.v21i5.2449; Kezic S, O’Regan GM, Yau N, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy. 2011;66(7):934–940. doi: https://doi.org/10.1111/j.1398-9995.2010.02540.x; Zeeuwen PL, Ederveen TH, Van Der Krieken DA, et al. Grampositive anaerobe cocci are underrepresented in the microbiome of filaggrin-deficient human skin. J Allergy Clin Immunol. 2017;139(4): 1368–1371. doi: https://doi.org/10.1016/j.jaci.2016.09.017; Emmert H, Baurecht H, Thielking F, et al. Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome. Exp Dermatol. 2021;30(10):1398–1408. doi: https://doi.org/10.1111/exd.14185; Clausen ML, Agner T, Lilje B, et al. Association of Disease Severity With Skin Microbiome and Filaggrin Gene Mutations in Adult Atopic Dermatitis. JAMA Dermatol. 2018;154(3):293–300. doi: https://doi.org/10.1001/jamadermatol.2017.5440; Baurecht H, Ruhlemann MC, Rodriguez E, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018;141(1):1668–1676. doi: https://doi.org/10.1016/j.jaci.2018.01.019; Мурашкин Н.Н., Амбарчян Э.Т., Материкин А.И., Епишев Р.В. Роль нарушений эпидермального барьера при атопическом дерматите: современные концепции патогенеза заболевания // Вопросы современной педиатрии. — 2018. — Т. 17. — № 1. — С. 85–88. — doi: https://doi.org/10.15690/vsp.v17i1.1859; Feuillie C, Vitry P, McAleer MA, et al. Adhesion of Staphylococcus aureus to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels. mBio. 2018;9(4):e01184-18. doi: https://doi.org/10.1128/mBio.01184-18; Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В. и др. Дефект филаггрина при атопическом дерматите: современные методы коррекции // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 347–351. — doi: https://doi.org/10.15690/vsp.v21i5.2452; Topical skin care compositions. Patent. Publication Number: WO 2018/198039 A1. Publication Date: 01.11.2018. International Application No: PCT/IB2018/052866. International Filing Date: 25.04.2018. Applicant: DR. REDDY’S LABORATORIES LIMITED.; Татаурщикова Н.С., Летяева О.И., Русанова А.С. Ведение пациентов с атопическим дерматитом в рутинной клинической практике // РМЖ. Медицинское обозрение. — 2022. — Т. 6. — № 2. — С. 72–78. — doi: https://doi.org/10.32364/2587-68212022-6-2-72-78; Аравийская Е.Р., Бакулев А.Л., Гаджигороева А.Г. и др. Практические вопросы применения эмолентов, содержащих модуляторы филаггрина, в ведении пациентов с атопическим дерматитом и ксерозом: резолюция Совета экспертов // Российский аллергологический журнал. — 2022. — Т. 19. — № 2. — С. 245–258. — doi: https://doi.org/10.36691/RJA1538

Availability: https://vsp.spr-journal.ru/jour/article/view/3298
https://doi.org/10.15690/vsp.v22i5.2619

Practical issues of using emollients for the prevention of exacerbations of atopic dermatitis during the flowering season: expert resolution ; Практические вопросы применения эмолентов с целью профилактики обострений атопического дерматита в сезон цветения: резолюция экспертов

Authors: E. S. Fedenko, I. N. Zakharova, O. V. Zaytseva, A. N. Pampura, O. B. Tamrazova, Е. С. Феденко, И. Н. Захарова, О. В. Зайцева, А. Н. Пампура, О. Б. Тамразова

Source: Meditsinskiy sovet = Medical Council; № 17 (2023); 172-178 ; Медицинский Совет; № 17 (2023); 172-178 ; 2658-5790 ; 2079-701X

Subject Terms: чрескожная сенсибилизация, emollients, epidermal barrier, pollen allergy, cutaneous sensitization, эмоленты, эпидермальный барьер, пыльцевая аллергия

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7837/6958; Кубанов АА, Намазова-Баранова ЛС, Хаитов РМ, Ильина НИ, Алексеева ЕА, Амбарчян ЭТ и др. Атопический дерматит: клинические рекомендации. М.; 2021. 81 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/265_2.; Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):8–16. https://doi.org/10.1159/000370220.; Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–992. https://doi.org/10.1111/j.1742-1241.2006.01047.x.; Liang Y, Chang C, Lu Q. The Genetics and Epigenetics of Atopic DermatitisFilaggrin and Other Polymorphisms. Clin Rev Allergy Immunol. 2016;51(3):315–328. https://doi.org/10.1007/s12016-015-8508-5.; Birben E, Sackesen C, Turgutoğlu N, Kalayci O. The role of SPINK5 in asthma related physiological events in the airway epithelium. Respir Med. 2012;106(3):349–355. https://doi.org/10.1016/j.rmed.2011.11.007.; Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int. 2018;67(1):3–11. https://doi.org/10.1016/j.alit.2017.10.002.; Ständer S. Atopic Dermatitis. N Engl J Med. 2021;384(12):1136–1143. https://doi.org/10.1056/NEJMra2023911.; Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324–338. https://doi.org/10.1007/s12016-021-08880-3.; Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017;13(1):15–26. https://doi.org/10.1080/1744666X.2016.1212660.; Hostetler SG, Kaffenberger B, Hostetler T, Zirwas MJ. The role of airborne proteins in atopic dermatitis. J Clin Aesthet Dermatol. 2010;3(1):22–31. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921737/.; Serhan N, Basso L, Sibilano R, Petitfils C, Meixiong J, Bonnart C et al. House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation. Nat Immunol. 2019;20(11):1435–1443. https://doi.org/10.1038/s41590-019-0493-z.; Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96–103.e9. https://doi.org/10.1016/j.jaci.2015.04.015.; Fölster-Holst R, Galecka J, Weißmantel S, Dickschat U, Rippke F, Bohnsack K et al. Birch pollen influence the severity of atopic eczema - prospective clinical cohort pilot study and ex vivo penetration study. Clin Cosmet Investig Dermatol. 2015;8:539–548. https://doi.org/10.2147/CCID.S81700.; Knaysi G, Smith AR, Wilson JM, Wisniewski JA. The Skin as a Route of Allergen Exposure: Part II. Allergens and Role of the Microbiome and Environmental Exposures. Curr Allergy Asthma Rep. 2017;17(1):7. https://doi.org/10.1007/s11882-017-0675-4.; Brough HA, Nadeau KC, Sindher SB, Alkotob SS, Chan S, Bahnson HT et al. Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented? Allergy. 2020;75(9):2185–2205. https://doi.org/10.1111/all.14304.; Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34(8):2100–2109. https://doi.org/10.1002/eji.200425196.; Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680. https://doi.org/10.1038/ni805.; Oyoshi MK, Larson RP, Ziegler SF, Geha RS. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin Immunol. 2010;126(5):976–984. https://doi.org/10.1016/j.jaci.2010.08.041.; Tordesillas L, Goswami R, Benedé S, Grishina G, Dunkin D, Järvinen KM et al. Skin exposure promotes a Th2-dependent sensitization to peanut allergens. J Clin Invest. 2014;124(11):4965–4975. https://doi.org/10.1172/JCI75660.; Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy. 2012;67(9):1118–1126. https://doi.org/10.1111/j.1398-9995.2012.02859.x.; Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. Allergy. 2018;73(10):2046–2054. https://doi.org/10.1111/all.13454.; Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol. 1999;104(2 Pt 1):466–472. https://doi.org/10.1016/s0091-6749(99)70395-7.; De Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–1036. https://doi.org/10.1111/jdv.16003.; Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, FinkWagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023.; Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060. https://doi.org/10.1111/j.1468-3083.2012.04635.x.; Giménez-Arnau A. Standards for the Protection of Skin Barrier Function. In: Agner T (ed.). Skin Barrier Function. Karger; 2016, pp. 123–134. https://doi.org/10.1159/000441588.; Guéniche A, Dahel K, Bastien P, Martin R, Nicolas JF, Breton L. Vitreoscilla filiformis bacterial extract to improve the efficacy of emollient used in atopic dermatitis symptoms. J Eur Acad Dermatol Venereol. 2008;22(6):746–747. https://doi.org/10.1111/j.1468-3083.2007.02428.x.; Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebocontrolled clinical study. Br J Dermatol. 2008;159(6):1357–1363. https://doi.org/10.1111/j.1365-2133.2008.08836.x.; Mainzer C, Le Guillou M, Vyumvuhore R, Chadoutaud B, Bordes S, Closs B. Clinical Efficacy of Oligofructans from Ophiopogon japonicus in Reducing Atopic Dermatitis Flare-ups in Caucasian Patients. Acta Derm Venereol. 2019;99(10):858–864. https://doi.org/10.2340/00015555-3224.; Meinke MC, Patzelt A, Richter H, Schanzer S, Sterry W, Filbry A et al. Prevention of follicular penetration: barrier-enhancing formulations against the penetration of pollen allergens into hair follicles. Skin Pharmacol Physiol. 2011;24(3):144–150. https://doi.org/10.1159/000323018.; Lademann J, Patzelt A, Richter H, Schanzer S, Sterry W, Filbry A et al. Comparison of two in vitro models for the analysis of follicular penetration and its prevention by barrier emulsions. Eur J Pharm Biopharm. 2009;72(3):600–604. https://doi.org/10.1016/j.ejpb.2009.02.003.; Billmann-Eberwein C, Rippke F, Ruzicka T, Krutmann J. Modulation of atopy patch test reactions by topical treatment of human skin with a fatty acid-rich emollient. Skin Pharmacol Appl Skin Physiol. 2002;15(2):100–104. https://doi.org/10.1159/000049396.; Литовкина АО, Смольников ЕВ, Елисютина ОГ, Феденко ЕС. Современные эмоленты в профилактике обострений атопического дерматита в сезон цветения. Российский аллергологический журнал. 2023;20(1):41–51. https://doi.org/10.36691/RJA4136.; Luger T, Amagai M, Dreno B, Dagnelie MA, Liao W, Kabashima K et al. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci. 2021;102(3):142–157. https://doi.org/10.1016/j.jdermsci.2021.04.007.; Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2018;178(1):e19–e21. https://doi.org/10.1111/bjd.15747

Availability: https://www.med-sovet.pro/jour/article/view/7837
https://doi.org/10.21518/ms2023-364

Scientific and Practical Innovations in Restoring Skin Barrier Properties in Children with Atopic Dermatitis ; Научно-практические инновации в технологии восстановления барьерных свойств кожи при атопическом дерматите у детей

Authors: Nikolay N. Murashkin, Roza Y. Nezhvedilova, Dmitri V. Fedorov, Roman V. Epishev, Roman A. Ivanov, Alexander I. Materikin, Leonid A. Opryatin, Alena A. Savelova, Lyudmila L. Rusakova, Н. Н. Мурашкин, Р. Ю. Нежведилова, Д. В. Федоров, Р. В. Епишев, Р. А. Иванов, А. И. Материкин, Л. А. Опрятин, А. А. Савелова, Л. Л. Русакова

Contributors: Not specified, Отсутствует

Source: Current Pediatrics; Том 21, № 5 (2022); 378-382 ; Вопросы современной педиатрии; Том 21, № 5 (2022); 378-382 ; 1682-5535 ; 1682-5527

Subject Terms: транскутанная сенсибилизация, atopic dermatitis, atopic march, epidermal barrier, Staphylococcus aureus, corneal layer, transcutaneous sensibilization, атопический дерматит, атопический марш, эпидермальный барьер, роговой слой

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3033/1227; Drucker AM, Wang AR, Li WQ, et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Asso ciation. J Investig Dermatol. 2017;137(1):26–30. doi: https://doi.org/10.1016/j.jid.2016.07.012; Maliyar K, Sibbald C, Pope E, et al. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538–550. doi: https://doi.org/10.1097/01.asw.0000547414.38888.8d; Xu X, van Galen LS, Koh MJ, et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: A cross-sectional study. Sci Rep. 2019;9(1):15990. doi: https://doi.org/10.1038/s41598-019-51129-5; Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy. 2006;61(8):969–987. doi: https://doi.org/10.1111/j.1398-9995.2006.01153.x; Abu-Dayyeh I, Abu-Kwaik J, Weimann A, Abdelnour A. Prevalence of IgE-mediated sensitization in patients with suspected food allergic reactions in Jordan. Immun Inflamm Dis. 2020;8(3): 384–392. doi: https://doi.org/10.1002/iid3.320; Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi: https://doi.org/10.2500/aap.2019.40.4202; Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–1070. doi: https://doi.org/10.1038/jid.2008.88; Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009;9(5):437–446. doi: https://doi.org/10.1097/ACI.0b013e32832e7d36; Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012; 122(2):440–447. doi: https://doi.org/10.1172/JCI57416; Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040; Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–357. doi: https://doi.org/10.1111/exd.13514; Bin L, Leung DY. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol. 2016;12:52. doi: https://doi.org/10.1186/s13223-016-0158-5; Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015;45(3):566–574. doi: https://doi.org/10.1111/cea.12495; Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x; Altrichter S, Kriehuber E, Moser J, et al. Serum IgE Autoantibodies Target Keratinocytes in Patients with Atopic Dermatitis. J Invest Dermatol. 2008;128(9):2232–2239. doi: https://doi.org/10.1038/jid.2008.80; Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347(8993):15–18. doi: https://doi.org/10.1016/s0140-6736(96)91556-1; McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. doi: https://doi.org/10.1016/j.jaci.2006.04.033; Nakatsuji T, Chen TH, Two AM, et al. Staphylococcus aureus Exploits Epidermal Barrier Defects in Atopic Dermatitis to Trigger Cytokine Expression. J Invest Dermatol. 2016;136(11):2192–2200. doi: https://doi.org/10.1016/j.jid.2016.05.127; Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibod ies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993;92(3):1374–1380. doi: https://doi.org/10.1172/JCI1167; Hauk PJ, Hamid QA, Chrousos GP, et al. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol. 2000;105(4):782–787. doi: https://doi.org/10.1067/mai.2000.105807; Egawa G, Weninger W. Pathogenesis of atopic dermatitis: A short review. Cogent Biology. 2015;1(1):1103459. doi: https://doi.org/10.1080/23312025.2015.1103459; Kezic S, Novak N, Jakasa I, et al. Skin barrier in atopic dermatitis. Fron Biosci (Landmark Ed). 2014;19(3):542–556. doi: https://doi.org/10.2741/4225; Adhikary PP, Tan Z, Page BDG, Hedtrich S. TSLP as druggable target — a silver-lining for atopic diseases? Pharmacol Ther. 2021;217: 107648. doi: https://doi.org/10.1016/j.pharmthera.2020.107648; Kubo A, Nagao K, Yokouchi M, et al. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med. 2009;206(13):2937–2946. doi: https://doi.org/10.1084/jem.20091527; Rutz S, Ouyang W. Regulation of Interleukin-10 Expression. In: Regulation of Cytokine Gene Expression in Immunity and Diseases. Ma X, ed. Springer Dordrecht; 2016. pp. 89–116. doi: https://doi.org/10.1007/978-94-024-0921-5_5; Rinaldi G. The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol Pract Concept. 2019;9(2):90–97. doi: https://doi.org/10.5826/dpc.0902a03; Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”. J Allergy Clin Immunol. 2019;143(3):894–913. doi: https://doi.org/10.1016/j.jaci.2019.01.003; Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19(7):614–618. doi: https://doi.org/10.1111/j.1399-3038.2007.00706.x; Eckert RL, Rorke EA. Molecular biology of keratinocyte differentiation. Environ Health Perspect. 1989;80:109–116. doi: https://doi.org/10.1289/ehp.8980109; Siddiqi KS, ur Rahman A, Tajuddin, Husen A. Properties of Zinc Oxide Nanoparticles and Their Activity Against Microbes. Nanoscale Res Lett. 2018;13(1):141. doi: https://doi.org/10.1186/s11671-018-2532-3; Chew SWT, Zeng Y, Cui M, et al. In Situ Generation of Zinc Oxide Nanobushes on Microneedles as Antibacterial Coating. SLAS Technol. 2018;24(2):181–187. doi: https://doi.org/10.1177/2472630318812350; Clement JL, Jarrett PS. Antibacterial Silver. Met Based Drugs. 1994;1(5-6):467–482. doi: https://doi.org/10.1155/MBD.1994.467; Wisniewski JA, Agrawal R, Minnicozzi S, et al. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis. Clin Exp Allergy. 2013;43(10): 1160–1170. doi: https://doi.org/10.1111/cea.12169

Availability: https://vsp.spr-journal.ru/jour/article/view/3033
https://doi.org/10.15690/vsp.v21i5.2457

Filaggrin and Atopic Dermatitis: Clinical and Pathogenetic Parallels and Therapeutic Possibilities ; Филаггрин и атопический дерматит: клинико-патогенетические параллели и возможности терапевтической коррекции

Authors: Nikolay N. Murashkin, Roman A. Ivanov, Eduard T. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Alena A. Savelova, Н. Н. Мурашкин, Р. А. Иванов, Э. Т. Амбарчян, Р. В. Епишев, А. И. Материкин, Л. А. Опрятин, А. А. Савелова

Contributors: Not specified., Не указан.

Source: Current Pediatrics; Том 20, № 5 (2021); 435-440 ; Вопросы современной педиатрии; Том 20, № 5 (2021); 435-440 ; 1682-5535 ; 1682-5527

Subject Terms: церамиды, filaggrin, emollient, filagrinol, epidermal barrier, corneal layer, ceramides, филаггрин, эмоленты, филагринол, эпидермальный барьер, роговой слой

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2749/1090; Maliyar K, Sibbald C, Pope E, et al. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538-550. doi:10.1097/01.asw.0000547414.38888.8d; Drucker AM, Wang AR, Li WQ, et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26-30. doi:10.1016/j.jid.2016.07.012; Xu X, van Galen LS, Koh MJ., et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: A crosssectional study. Sci Rep. 2019;9(1):15990. doi:10.1038/s41598-019-51129-5; Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. Allergol Immunopathol. 2013;41(2):73-85. doi:10.1016/j.aller.2012.03.001; Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743. doi:10.1016/s0140-6736(06)69283-0; Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22(1):1-24. doi:10.1016/s0889-8561(03)00066-3; National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) body composition procedures manual. Centers for Disease Control and Prevention. Hyattsville, MD; 2006.; Deckers I.A., McLean S., Linssen S., et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: A systematic review of epidemiologic studies. PLoS One. 2012;7(7):e39803. doi:10.1371/journal.pone.0039803; Kowalska-Olędzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126-128. doi:10.1080/21556660.2019.1619570; Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73. doi:10.1038/jid.2010.251; Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi:10.3390/ijms21082867; Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440-447. doi:10.1172/JCI57416; Michael JC, Simon GD, Yiannis V, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. doi:10.1038/jid.2009.133; Bosko CA. Skin Barrier Insights: From Bricks and Mortar to Molecules and Microbes. J Drugs Dermatol. 2019;18(1s):s63-s67.; Wickett RR, Visscher MO. Structure and function of the epidermal barrier. Am J Infect Control. 2006;34(10):S98-S110. doi:10.1016/j.ajic.2006.05.295; Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27(6):269-280. doi:10.1093/intimm/dxv013; Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest. 2006;116(5):1150-1158. doi:10.1172/JCI28521; Natsuga K. Epidermal barriers. Cold Spring Harb Perspect Med. 2014;4(4):a018218. doi:10.1101/cshperspect.a018218; Munoz-Garcia A, Thomas CP Keeney DS, et al. The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier. Biochim Biophys Acta. 2014;1841(3):401-408. doi:10.1016/j.bbalip.2013.08.020; Nakagawa N, Sakai S, Matsumoto M, et al. Relationship between NMF (lactate and potassium) content and the physical properties of the stratum corneum in healthy subjects. J Invest Dermatol. 2004;122(3):755-763. doi:10.1111/j.0022-202X.2004.22317.x; Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi:10.3390/ijms22084130; Presland RB, Haydock PV, Fleckman P, et al. Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus. J Biol Chem. 1992;267:23772-23781.; Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446. doi:10.1038/ng1767; Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;27(2):128-137. doi:10.1016/j.sder.2008.04.001; Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382-402. doi:10.3390/children2030382; Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60(1):1-9. doi:10.2332/allergolint.10-RAI-0270; Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol. 2009;129(3):543-552. doi:10.1038/jid.2008.413; O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122(4):689-693. doi:10.1016/j.jaci.2008.08.002; Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-1327. doi:10.1056/NEJMra1011040; McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649-655. doi:10.4103/0019-5154.193674; McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280-291. doi:10.1016/j.jaci.2012.12.668; Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):6773. doi:10.4168/aair.2011.3.2.67; Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi:10.1371/journal.pmed.1001748; Irvine A.D., Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide. Br J Dermatol. 2019;181(5):895-906. doi:10.1111/bjd.17766; Chan A, Terry W, Zhang H, et al. Filaggrin mutations increase allergic airway disease in childhood and adolescence through interactions with eczema and aeroallergen sensitization. Clin Exp Allergy. 2018;48(2):147-155. doi:10.1111/cea.13077; Venkataraman D, Soto-Ramfrez N, Kurukulaaratchy RJ, et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol. 2014;134(4):876-882.e4. doi:10.1016/j.jaci.2014.07.033; Rodnguez E, Baurecht H, Herberich E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol. 2009;123(6):1361-1370. e7. doi:10.1016/j.jaci.2009.03.036; Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filag-grin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6):1184-1190. doi:10.1016/j.jaci.2010.09.015; Rabinowitz LG, Esterly NB. Atopic dermatitis and ichthyosis vulgaris. Pediatr Rev. 1994;15(6):220-226; quiz 226. doi:10.1542/pir.15-6-220; Sehgal VN, Khurana A, Mendiratta V, et al. Atopic dermatitis: Clinical connotations, especially a focus on concomitant atopic undertones in immunocompromised/susceptible genetic and metabolic disorders. Indian J Dermatol. 2016;(61):241-250. doi:10.4103/0019-5154.182433; Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150-155. doi:10.1016/j.jaci.2007.04.031; Arakawa H, Shimojo N, Katoh N, et al. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergol Int. 2020;69(1):84-90. doi:10.1016/j.alit.2019.08.006; Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.; Reda AM, Ayman E, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East empha-sizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366-373. doi:10.1080/09546634.2018.1524823; Catherine M., Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi:10.1155/2012/836931; Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023; Hebert AA, Rippke, F, Weber TM, et al. Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence. Am J Clin Dermatol. 2020;21(5):641-655. doi:10.1007/s40257-020-00529-9; Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. doi:10.1016/j.jaad.2009.11.011; Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. doi:10.1016/j.jaci.2014.08.005; Lowe A, Su J, Tang M, et al. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open. 2019;9(3):e024594. doi:10.1136/bmjopen-2018-024594; L0drup Carlsen KC, Rehbinder EM, Skjerven HO, et al. Preventing atopic dermatitis and ALLergies in children — the PreventADALL study. Allergy. 2018; 73(10):2063-2070. doi:10.1111/all.13468; Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review. Clin Med Res. 2017;15(3-4):75-87. doi:10.3121/cmr.2017.1363; Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61-67. doi:10.1159/000096915; Hon KL, Pong NH, Wang SS, et al. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D. 2013;13(1):37-42. doi:10.1007/s40268-013-0004-x; Wollenberg A, Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32 (Suppl 1):1-15. doi:10.1111/jdv.14846; Topical skin care compositions. Patent. Publication Number: WO 2018/198039 A1. Publication Date: 01.11.2018. International Application No: PCT/IB2018/052866. International Filing Date: 25.04.2018. Applicant: DR. REDDY'S LABORATORIES LIMITED.; Mohammed D, Crowther JM, Matts PJ, et al. Influence of niacinamide containing formulations on the molecular and biophysical properties of the stratum corneum. Int J Pharm. 2013;441(1-2):192-201. doi:10.1016/j.ijpharm.2012.11.043; Coderch L, Lopez O, de la Maza A, Parra JL. Ceramides and skin function. Am J Clin Dermatol. 2003;4(2):107-129. doi:10.2165/00128071-200304020-00004; Kim ME, Kim HK, Kim DH, et al. Glycyrrhetinic acid from licorice root impairs dendritic cells maturation and Th1 immune responses. Immunopharmacol Immunotoxicol. 2013;35(3):329-335. doi:10.3109/08923973.2013.768636; Akihisa T, Kojima N, Kikuchi T, et al. Anti- inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat. J Oleo Sci. 2010;59(6):273-280. doi:10.5650/jos.59.273; Scapagnini G, Davinelli S, Di Renzo L, et al. Cocoa bioactive compounds: significance and potential for the maintenance of skin health. Nutrients. 2014;6(8):3202-3213. doi:10.3390/nu6083202; Abril-Gil M, Massot-Cladera M, Perez-Cano FJ, et al. A diet enriched with cocoa prevents IgE synthesis in a rat allergy model. Pharmacol Res. 2012;65(6):603-608. doi:10.1016/j.phrs.2012.02.001; Mandawgade SD, Patravale VB. Formulation and evaluation of exotic fat based cosmeceuticals for skin repair. Indian J Pharm Sci. 2008;70(4):539-542. doi:10.4103/0250-474X.44615

Availability: https://vsp.spr-journal.ru/jour/article/view/2749
https://doi.org/10.15690/vsp.v20i5.2320

The Role of Minor Signs in Atopic Dermatitis Diagnostics ; Значение «малых» признаков в диагностике атопического дерматита

Authors: Olga B. Tamrazova, Sergey P. Seleznev, Anait V. Tamrazova, О. Б. Тамразова, С. П. Селезнёв, А. В. Тамразова

Contributors: The article has been funded by Pierre Fabre., Статья опубликована при поддержке компании «Пьер Фабр».

Source: Current Pediatrics; Том 19, № 3 (2020); 235-243 ; Вопросы современной педиатрии; Том 19, № 3 (2020); 235-243 ; 1682-5535 ; 1682-5527

Subject Terms: экскориации, epidermal barrier, diagnostics, minor signs, disruptions, excoriations, эпидермальный барьер, диагностика, «малые» критерии, трещины

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2425/947; Deleuran M, Vestergaard C. Clinical heterogeneity and differential diagnosis of atopic dermatitis. Br J Dermatol. 2014; 170 Suppl 1:2–6. doi:10.1111/bjd.12933.; Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi:10.1111/bjd.16934.; Garg N, Silverberg JI. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):281–288. doi:10.1016/j.clindermatol.2014.12.004.; Кубанова А.А., Кубанов А.А., Мелехина Л.Е., Богданова Е.В. Анализ состояния заболеваемости болезнями кожи и подкожной клетчатки в Российской Федерации за период 2003–2016 гг. // Вестник дерматологии и венерологии. — 2017. — № 6. — С. 22–33. doi:10.25208/0042-4609-2017-93-6-22-33.; Смирнова Г.И. Атопический дерматит и инфекции кожи у детей // Российский педиатрический журнал. — 2014. — № 2. — С. 49–56.; Mier PD. Earliest description of the atopic syndrome? Br J Dermatol. 1975;92:359. doi:10.1111/j.1365-2133.1975.tb03091.x; Kramer ON, Strom MA, Ladizinski B, Lio P A. The history of atopic dermatitis. Clin Dermatol. 2017;35(4):344–348. doi:10.1016/j.clindermatol.2017.03.005.; Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol. 1923;8(3):163–182.; Wise F, Sulzberger MB. Year Book of Dermatology and Syphilology. Chicago: Year Book Publishers; 1933. pp. 38–39.; Mayba J., Gooderham M J. (2016). Review of Atopic Dermatitis and Topical Therapies. J Cutan Med Surg. 2017;21(3):227–236. doi:10.1177/1203475416685077.; Tham EH, Leung DYM. Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March. Allergy Asthma Immunol Res. 2019;11(1):4–15. doi:10.4168/aair.2019.11.1.4.; Атопический дерматит у детей. Клинические рекомендации. Союз педиатров России; Российская ассоциация аллергологов и клинических иммунологов; 2016. Доступно по: https://www.pediatr-russia.ru/information/klin-rek/deystvuyushchie-klinicheskie-rekomendatsii/АтД%20дети%20СПР.v2.pdf. Ссылка активна на 20.07.2020.; Fiset P-O, Leung DYM, Hamid Q. Immunopathology of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):287–290. doi:10.1016/j.jaci.2006.03.046.; McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. doi:10.1016/j.jaci.2006.04.033.; Cork M, Danby S, Vasilopoulos Y, et al. Epidermal Barrier Dysfunction in Atopic Dermatitis. J Invest Dermatol. 2009;129(8): 1892–1908. doi:10.1038/jid.2009.133.; Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi:10.1038/ng1767.; Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 2010; 125(1):16–29. doi:10.1016/j.jaci.2009.11.008.; Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE mediated food allergy among children with atopic dermatitis. Pediatrics. 1998;101(3):E8. doi:10.1542/peds.101.3.e8.; Suh KY. Food allergy and atopic dermatitis: separating fact from fiction. Semin Cutan Med Surg. 2010;29(2):72–78. doi:10.1016/j.sder.2010.03.007.; Варламов Е.Е., Пампура А.Н., Сухоруков В.С. Значение цитокинов в патогенезе атопического дерматита. Российский вестник перинатологии и педиатрии // 2018. — Т. 63. — № 1. — С. 28–33. doi:10.21508/1027-4065-2018-63-1-28-33.; Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762. doi:10.1038/jid.2011.393.; Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the ‘fused genes’ family. Exp Dermatol. 2012;21(9):643–649. doi:10.1111/j.1600-0625.2012.01472.x.; Gavrilova T. Immune Dysregulation in the Pathogenesis of Atopic Dermatitis. Dermatitis. 2018;29(2):57–62. doi:10.1097/DER.0000000000000340.; Seltmann J, Roesner LM, Von Hesler FW, et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659–1661. doi:10.1016/j.jaci.2015.01.048.; Тамразова О.Б., Гуреева М. А., Кузнецова Т.А., Воробьева А.С. Возрастная эволютивная динамика атопического дерматита // Педиатрия. — 2016. — № 1. — С. 153–159.; Lee S-C. Various diagnostic criteria for atopic dermatitis (AD): A proposal of Reliable Estimation of Atopic Dermatitis in Childhood (REACH) criteria, a novel questionnaire-based diagnostic tool for AD. J Dermatol. 2016;43(4):376–384. doi:10.1111/1346-8138.13264.; Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;Suppl 59:44–47.; Федеральные клинические рекомендации по ведению больных атопическим дерматитом. М.: Российское общество дерматовенерологов и косметологов; 2015.; Pennycook KB, McCready TA. Keratosis Pilaris. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; 2019.; Jadotte YT, Janniger CK. Pityriasis alba revisited: perspectives on an enigmatic disorder of childhood. Cutis. 2011;87(2):66–72.; Miazek N, Michalek I, Pawlowska-Kisiel M, et al. Pityriasis Alba — Common Disease, Enigmatic Entity: Up-to-Date Review of the Literature. Pediatr Dermatol. 2015;32(6):786–791. doi:10.1111/pde.12683.; Sarifakioglu E. Extensive pityriasis alba in a nonatopic child. Pediatr Dermatol. 2007;24(2):199–200. doi:10.1111/j.1525-1470.2007.00379.x.; Луцкая И.К. Клинические проявления самостоятельных заболеваний губ // Медицинские новости. — 2011. — № 11. — С. 4–8.; Fenner J, Silverberg NB. Skin diseases associated with atopic dermatitis. Clin Dermatol. 2018;36(5):631–640. doi:10.1016/j.clindermatol.2018.05.004.; Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact Dermatitis. 2008;58(6):330–334. doi:10.1111/j.1600-0536.2008.01345.x.; Lerbaek A, Kyvik KO, Ravn H, et al. Clinical characteristics and consequences of hand eczema — an 8-year follow-up study of a population-based twin cohort. Contact Dermatitis. 2008;58(4): 210–216. doi:10.1111/j.1600-0536.2007.01305.x.; Totte JEE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4): 687–695. doi:10.1111/bjd.14566.; Wan P, Chen J, Calm A. Dispassionate Look at Skin Microbiota in Atopic Dermatitis: An Integrative Literature Review. Dermatol Ther (Heidelb). 2020;10(1):53–61. doi:10.1007/s13555-020-00352-4.; Стадникова А.С., Тамразова О.Б., Чеботарева Т.А. Клинико-анамнестические критерии ранней диагностики герпетической экземы у детей с атопическим дерматитом // Альманах клинической медицины. — 2018. — Т. 46. — № 2. — С. 126–131. doi:10.18786/2072-0505-2018-46-2-126-13.; Мачарадзе Д.Ш. Атопический дерматит: новое в лечении // Вопросы современной педиатрии. — 2013. — Т. 12. — № 5. — С. 80–85.; Жерносек В.Ф. Антилейкотриеновые препараты в лечении атопического дерматита и крапивницы у детей // Медицинские новости. — 2015. — № 11. — С. 4–7.; Боброва Н.Ф. Классификация врожденных катаракт (клинико-хирургическая) // Российская педиатрическая офтальмология. — 2012. — № 2. — C. 52–57.; Fournie P, Touboul D, Arne JL, et al. Keratocone [Keratoconus]. J Fr Ophtalmol. 2013;36(7):618–626. doi:10.1016/j.jfo.2013.05.004.; Атопический дерматит. Руководство для врачей / под ред. Ю.В. Сергеева. М.: Медицина для всех; 2003. 183 с.; Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children: Part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi:10.1111/jdv.14891.; Wollenberg A, Folster-Holst R, Saint Aroman M, et al. Effects of a Protein-Free Oat Plantlet Extract on Microinflammation and Skin Barrier Function in Atopic Dermatitis Patients. J Eur Acad Dermatol Venereol. 2018;32 Suppl 1:1–15. doi:10.1111/jdv.14846.; Mandeau A, Aries M-F, Boe J-F, et al. Rhealba® Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators. Planta Med. 2011;77(9):900–906. doi:10.1055/s-0030-1250649.; Saint Aroman M. News about Emollients with Rhealba Oat Plantlets Extract: Prevention and Treatment of Atopic Dermatitis. Journal of Clinical Pediatrics and Neonatal Care [Internet]. Available online: https://jacobspublishers.com/journals/journal-of-clinicalpediatrics-and-neonatal-care/fulltext/news-about-emollients-withrhealba-oat-plantlets-extract-prevention-and-treatment-of-atopicdermatitis. Accessed on July 8, 2020.; Aries MF, Vaissiere C, Pinelli E. Avena Rhealba inhibits A23187-stimulated arachidonic acid mobilization, eicosanoid release, and cPLA2 expression in human keratinocytes: potential in cutaneous inflammatory disorders. Biol Pharm Bull. 2005;28(4):601–606. doi:10.1248/bpb.28.601.; Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children: Part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi:10.1111/jdv.14888.; Theunis J, Chaussade H, Bourgeois O, et al. Efficacy of a Rhealba® Oat extract-based emollient on chronic pruritus in elderly French outpatients. J Eur Acad Dermatol Venereol. 2017;31 Suppl 1: 1–7. doi:10.1111/jdv.14077.; Ribet V, Mielewczyk E, Sirvent A, et al. A novel dermo-cosmetic product containing thermal spring water, sucralfate, copper sulfate, and zinc sulfate in the management of hand eczema. Clin Cosmet Investig Dermatol. 2018;11:373–381. doi:10.2147/CCID.S157849.; Пашинян А.Г., Эффективность применения средств дерматологической косметики у пациентов с хроническими дерматозами // Российский журнал кожных и венерических болезней. — 2015. — Т. 18. — № 4. — С. 48–55.; Renzi C, Abeni D, Picardi A, et al. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol. 2001;145(4):617–623. doi:10.1046/j.1365-2133.2001.04445.x.; Хлебникова А.Н., Петрунин Д.Д. Цинк, его биологическая роль и применение в дерматологии // Вестник дерматологии и венерологии. — 2013. — № 6. — С. 100–116.; Brandrup F, Menne T, Agren M, et al. A randomized trial of two occlusive dressings in the treatment of leg ulcers. Acta Derm Venereol. 1990;70(3):231–235.; Agren M. Studies on zinc in wound healing. Acta Derm Venereol Suppl (Stockh). 1990;154:1–36.; Banatia A, Chowdhurya SR, Mazumderb S. Topical use of Sucralfate Cream in second and third degree burns. J Burns. 2001; 27(5):465–469. doi:10.1016/s0305-4179(00)00165-0.

Availability: https://vsp.spr-journal.ru/jour/article/view/2425
https://doi.org/10.15690/vsp.v19i3.2120

Modern View on the Role of Epidermal Barrier in Atopic Phenotype Development in Children ; Современные представления о роли эпидермального барьера в развитии атопического фенотипа у детей

Authors: Nikolay N. Murashkin, Alena A. Savelova, Roman A. Ivanov, Dmitri V. Fedorov, Leonid A. Opryatin, Wasel Ahmad, Н. Н. Мурашкин, А. А. Савелова, Р. А. Иванов, Д. В. Федоров, Л. А. Опрятин, В. Ахмад

Contributors: The article has been supported by Pierre Fabre LLC, Статья опубликована при поддержке ООО «Пьер Фабр»

Source: Current Pediatrics; Том 18, № 5 (2019); 386-392 ; Вопросы современной педиатрии; Том 18, № 5 (2019); 386-392 ; 1682-5535 ; 1682-5527

Subject Terms: транскутанная IgE-сенсибилизация, epidermal barrier, TJs, transepidermal water loss, keratinocytes, filaggrin, stratum corneum, lipid plates, transmembrane proteins, skin pH, transcutaneous IgE-sensibilization, эпидермальный барьер, трансэпидермальная потеря воды, кератиноциты, филаггрин, роговой слой, липидные пластины, трансмембранные белки, pH кожи

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2238/900; Elias PM, Steinhoff M. «Outside-to-inside» (and now back to «outside») pathogenic mechanisms in atopic dermatitis. J Inv Derm. 2008;128(5):1067-1070. doi:10.1038/jid.2008.88.; Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology / American Academy of Allergy, Asthma and Immunology / PRACTALL consensus report. Allergy. 2006;61(8):969-987. doi:10.1111/j.1398-9995.2006.01153.x.; Morar N, Willis-Owen SA, Moffatt MF, Cookson WO. The genetics of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):24-34. doi:10.1016/j.jaci.2006.03.037.; Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27(6): 269-280. doi:10.1093/intimm/dxv013.; Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int. 2018;67(1):3-11. doi:10.1016/j.alit.2017.10.002.; Lund CH, Kuller J, Lane AT, et al. Neonatal skin care: evaluation of the AWHONN/NANN research-based practice project on knowledge and skin care practices. Association of Women's Health, Obstetric and Neonatal Nurses/National Association of Neonatal Nurses. J Obstet Gynecol Neonatal Nurs. 2001;30(1):30-40. doi:10.1177/088421701129003842.; Lund CH, Osborne JW, Kuller J, et al. Neonatal skin care: clinical outcomes of the AWHONN/NANN evidence-based clinical practice guideline. Association of Women's Health, Obstetric and Neonatal Nurses and the National Association of Neonatal Nurses. J Obstet Gynecol Neonatal Nurs. 2001;30(1):41-51. doi:10.1177/088421701129003851.; Zhao LP Di Z, Zhang L, et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in Northeast China. J Eur Acad Dermatol Venereol. 2012;26(5):572-577. doi:10.1111/j.1468-3083.2011.04120.x.; O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122(4):689-693. doi:10.1016/j.jaci.2008.08.002.; Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 2004;17 Suppl 1:43-48. doi:10.1111/j.1396-0296.2004.04s1005.x.; Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792-799. doi:10.1016/ j.jaci.2014.06.014.; Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filag-grin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6): 1184-1190.e3. doi:10.1016/j.jaci.2010.09.015.; Hammarlund K, Sedin G, Stromberg B. Transepidermal water loss in newborn infants. VIII. Relation to gestational age and postnatal age in appropriate and small for gestational age infants. Acta Paediatr Scand. 1983;72(5):721-728. doi:10.1111/j.1651-2227.1983.tb09801.x.; Irvine AD, Hoeger PH, Yan AC. Harper’s Textbook of Pediatric Dermatology. Wiley-Blackwell; 2011.; McCall EM, Alderdice F, Halliday HL, et al. Interventions to prevent hypothermia at birth in preterm and/or low birthweight infants. Cochrane Database Syst Rev. 2010;(3):CD004210. doi:10.1002/14651858.CD004210.pub4.; Eichenfield LF, Frieden IJ, Mathes E, Zaenglein A. Neonatal and Infant Dermatology. Elsevier Inc; 2015. 752 р.; Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: beyond filaggrin. An Bras Dermatol. 2016;91(4): 472-478. doi:10.1590/abd1806-4841.20164412.; Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol. 2011;127(3):661-667. doi:10.1016/j.jaci.2011.01.031.; Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007;18(9): 3607-3619. doi:10.1091/mbc.e07-02-0124.; Looman KIM, van Meel ER, Grosserichter-Wagener C, et al. Associations of Th2, Th17, Treg cells, and IgA + memory B cells with atopic disease in children: the generation R study. Allergy. 2019 Aug 6. doi:10.1111/all.14010.; Filho GH, Cunhain PR. Fogo Selvagem (Endemic Pemphigus Foliaceus). In: Tyring SK. Tropical Dermatology (Second Edition). Elsevier; 2017.; Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet. 2013;45(10):1244-1248. doi:10.1038/ng.2739.; Oji V, Eckl KM, Aufenvenne K, et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet. 2010;87(2):274-281. doi:10.1016/j.ajhg.2010.07.005.; Brattsand M, Stefansson K, Lundh C, et al. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol. 2005;124(1):198-203. doi:10.1111/j.0022-202X.2004.23547.x.; Krieg P Furstenberger G. The role of lipoxygenases in epidermis. Biochim Biophys Acta. 2014;1841(3):390-400. doi:10.1016/j.bbalip.2013.08.005.; Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350-358.e1. doi:10.1016/j.jaci.2016.06.002.; Sasaki T, Shiohama A, Kubo A, et al. A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis. J Allergy Clin Immunol. 2013;132(5):1111-1120.e4. doi:10.1016/j.jaci.2013.08.027.; Saunders SP, Goh CS, Brown SJ, et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol. 2013;132(5):1121-1129. doi:10.1016/j.jaci.2013.08.046.; Skabytska Y, Kaesler S, Volz T, Biedermann T. The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments. Semin Immunopathol. 2016;38(1): 29-43. doi:10.1007/s00281-015-0544-y.; Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11): 1173-1179. doi:10.1038/nm1315.; Schroder K, Tschopp J. The inflammasomes. Cell. 2010; 140(6):821-832. doi:10.1016/j.cell.2010.01.040.; De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol. 2009;129(1):14-30. doi:10.1038/jid.2008.259.; Weidinger S, Klopp N, Rummler L, et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol. 2005;116(1):177-184. doi:10.1016/j.jaci.2005.02.034.; Weidinger S, Klopp N, Rummler L, et al. Association of CARD15 polymorphisms with atopy-related traits in a population based cohort of Caucasian adults. Clin Exp Allergy. 2005;35(7):866-872. doi:10.1111/j.1365-2222.2005.02269.x.; Gschwandtner M, Mildner M, Mlitz V, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy. 2013;68(1):37-47. doi:10.1111/all.12051.; Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 down-regulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2): 104-110. doi:10.1111/j.1600-0625.2011.01412.x.; Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. Interleukin-22 downregulates filaggrin expression and affects expression of profil-aggrin processing enzymes. Br J Dermatol. 2011;165(3):492-498. doi:10.1111/j.1365-2133.2011.10400.x.; Orfali RL, Sato MN, Takaoka R, et al. Atopic dermatitis in adults: evaluation of peripheral blood mononuclear cells proliferation response to Staphylococcus aureus enterotoxins A and B and analysis of interleukin-18 secretion. Exp Dermatol. 2009;18(7): 628-633. doi:10.1111/j.1600-0625.2009.00842.x.; Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7-R12. doi:10.1016/j.jaci.2009.07.012.; Hadj-Rabia S, Baala L, Vabres P et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology. 2004;127(5):1386-1390. doi:10.1053/j.gastro.2004.07.022.; Turksen K, Troy TC. Barriers built on claudins. J Cell Sci. 2004;117(Pt 12):2435-2447. doi:10.1242/jcs.01235.; Yuki T, Yoshida H, Akazawa Y, et al. Activation of TLR2 enhances tight junction barrier in epidermal keratinocytes. J Immunol. 2011;187(6):3230-3237. doi:10.4049/jimmunol.1100058.; De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773-786.e1-7. doi:10.1016/j.jaci.2010.10.018.; Yokouchi M, Kubo A, Kawasaki H, et al. Epidermal tight junction barrier function is altered by skin inflammation, but not by filag-grindeficient stratum corneum. J Dermatol Sci. 2015;77(1):28-36. doi:10.1016/j.jdermsci.2014.11.007.; Aries MF, Vaissiere C, Delga H, et al. Antiinflammatory and immunomodulatory effects of I-modulia, an Aquaphilus dolomiae extract, on atopic dermatitis in vitro. J Am Acad Dermatol. 2014; 70(5 Suppl 1):АВ61. doi:10.1016/j.jaad.2014.01.253.; Nguyen T, Castex-Rizzi N, Redoules D. Activites immunomodula-trice, anti-inflammatoire, antiprurigineuse et tolerogenique induites par I-modulia, un extrait issu de culture dAquaphilus dolomi-ae, dans les modeles pharmacologiques de dermatite atopique. Ann Derm Vеnеrеol. 2017;144:S42-S49. doi:10.1016/s01519638(17)31042-6.

Availability: https://vsp.spr-journal.ru/jour/article/view/2238
https://doi.org/10.15690/vsp.v18i5.2064

Role of Emollients in Prevention of the Comorbid Allergic Diseases Development in Children with Atopic Dermatitis ; Роль эмолентов в предотвращении развития аллергических заболеваний на фоне атопического дерматита у детей

Authors: Nikolay N. Murashkin, Roman A. Ivanov, Dmitri V. Fedorov, Eduard T. Ambarchyan, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Alena A. Savelova, Н. Н. Мурашкин, Р. А. Иванов, Д. В. Фёдоров, Э. Т. Амбарчян, Р. В. Епишев, А. И. Материкин, Л. А. Опрятин, А. А. Савелова

Contributors: The article has been supported by Pierre Fabre LLC., Статья опубликована при поддержке компании Pierre Fabre.

Source: Pediatric pharmacology; Том 17, № 4 (2020); 334-339 ; Педиатрическая фармакология; Том 17, № 4 (2020); 334-339 ; 2500-3089 ; 1727-5776

Subject Terms: эмоленты, epidermal barrier, atopic march, emollients, эпидермальный барьер, атопический марш

File Description: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/1885/1175; McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649–655. doi:10.4103/0019-5154.193674.; Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy Asthma Immunol Res. 2015;7(2):101–105. doi:10.4168/aair.2015.7.2.101.; Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106. doi:10.1016/j.anai.2009.10.002.; Jianu E, Ulmeanu R. Links between allergic rhinitis and asthma. Romanian Journal of Rhinology. 2013;3(9):39–44.; Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3):340–347. doi:10.1016/j.anai.2018.07.006.; Spergel J. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118–S127. doi:10.1016/j.jaci.2003.09.033.; Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии. Вопросы современной педиатрии. 2016;15(3):279–294. doi:10.15690/vsp.v15i3.1566.; Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225–1232.; Pols DHJ, Wartna JB, Moed H, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2): 143–150. doi:10.3109/02813432.2016.1160629.; Kijima A, Murota H, Takahashi A, et al. Prevalence and Impact of Past History of Food Allergy in Atopic Dermatitis. Allergol Int. 2013;62(1):105–112. doi:10.2332/allergolint.12-oa-0468.; Dhar S, Srinivas SM. Food Allergy in Atopic Dermatitis. Indian J Dermatol. 2016;61(6):645–648. doi:10.4103/0019-5154.193673.; Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol. 2001;108(5):720–725. doi:10.1067/mai.2001.119151.; Celakovska J, Bukac J. Analysis of food allergy in atopic dermatitis patients — association with concomitant allergic diseases. Indian J Dermatol. 2014;59(5):445–450. doi:10.4103/0019-5154.139867.; Pols DHJ, Wartna JB, van Alphen EI, et al. Interrelationships between Atopic Disorders in Children: A Meta-Analysis Based on ISAAC Questionnaires. PloS One. 20152;10(7):e0131869. doi:10.1371/journal.pone.0131869.; Lau S, Nickel R, Niggemann B, et al. The development of child-hood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatr Respir Rev. 2002;3(3):265–272. doi:10.1016/s1526-0542(02)00189-6.; Kulig M, Bergmann R, Klettke U, et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol. 1999;103(6):1173–1179. doi:10.1016/s0091-6749(99)70195-8.; Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi:10.2500/aap.2019.40.4202.; Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009; 9(5):437–446. doi:10.1097/ACI.0b013e32832e7d36.; Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi:10.3390/ijms21082867.; Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–1070. doi:10.1038/jid.2008.88.; Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest. 2007;117(12): 3655–3657. doi:10.1172/JCI34182.; Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation. Front Immunol. 2015;6:353. doi:10.3389/fimmu.2015.00353.; Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol. 2001;137(8):1079–1081.; Мурашкин Н.Н., Иванов Р.А., Савелова А.А. и др. Роль эпидермального барьера в формировании пищевой аллергии у детей с генодерматозами. Педиатрическая фармакология. — 2019. — Т. 16. — № 4. — С. 234–240. doi:10.15690/pf.v16i4.2053.; McAleer MA, Pohler E, Smith FJD, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268–1276. doi:10.1016/j.jaci.2015.05.002.; Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immu nol. 2007;120(1):150–155. doi:10.1016/j.jaci.2007.04.031.; Kobayashi J, Inai T, Morita K, et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine. 2004;28(4–5):186–189. doi:10.1016/j.cyto.2004.08.003.; Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factoralpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124(4):786–792. doi:10.1111/j.0022-202X.2005.23651.x.; Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi:10.1016/j.jaci.2005.10.033.; Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol. 2001;145(2):302–305. doi:10.1046/j.1365-2133.2001.04352.x.; Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49–50. doi:10.1016/j.it.2013.12.001.; Rinaldi G. The Itch-Scratch Cycle: A Review of the Mecha nisms. Dermatol Pract Concept. 2019;9(2):90–97. doi:10.5826/dpc.0902a03.; Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8–13. doi:10.1016/j.alit.2016.10.005.; Feld M, Garcia R, Buddenkotte J, et al. The pruritusand TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.e24. doi:10.1016/j.jaci.2016.02.020.; Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol. 1998;28(3):769–779. doi:10.1002/(SICI)1521-4141(199803)28:033.0.CO;2-H.; Lowe AJ, Leung DYM, Tang MLK, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi:10.1016/j.anai.2017.11.023.; Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440–447. doi:10.1172/JCI57416.; Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999;104(6):1280–1284. doi:10.1016/s0091-6749(99)70025-4.; De Benedetto A, Kubo A, Beck LA. Skin Barrier Disruption: A Requirement for Allergen Sensitization? J Invest Dermatol. 2012; 132(3):949–963. doi:10.1038/jid.2011.435.; Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382–402. doi:10.3390/children2030382.; Chin S, Vickery BP. Pathogenesis of food allergy in the pediatric patient. Curr Allergy Asthma Rep. 2012;12(6):621–629. doi:10.1007/s11882-012-0296-x.; Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. doi:10.1016/j.alit.2016.12.002.; Zhang Y, Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res. 2012;52(3):211–223. doi:10.1007/s12026-012-8264-z.; Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol. 2014;10(11):1463–1474. doi:10.1586/1744666X.2014.967684.; Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202(4):541–549. doi:10.1084/jem.20041503.; Kjellman NI, Nilsson L. From food allergy and atopic dermatitis to respiratory allergy. Pediatr Allergy Immunol. 1998;9(11 Suppl):13–17.; Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587–593. doi:10.1016/j.jaad.2009.11.011.; Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023.; Simpson EL. Atopic dermatitis: a review of topical treatment options. Cur Med Res Opin. 2010;26(3):633–640. doi:10.1185/03007990903512156.; van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017; 2(2):CD012119. doi:10.1002/14651858.CD012119.pub2.; Mack Correa CM, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi:10.1155/2012/836931.; Cork MJ, Danby S. Aqueous cream damages the skin barrier. Br J Derma tol. 2011;164(6):1179–1180. doi:10.1111/j.1365-2133.2011.10390.x.; Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2017;178(1):e19–e21. doi:10.1111/bjd.15747.; Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi:10.1111/jdv.14891.; Левина Ю.Г., Алексеева А.А., Эфендиева К.Е., Вишнёва Е.А., Намазова-Баранова Л.С. Коррекция дисбиоза кожи как неотъемлемая составная часть патогенетической терапии атопического дерматита. Педиатрическая фармакология . 2019; 16(2):97–100. doi:10.15690/pf.v16i2.2006; Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi:10.1016/s0140-6736(15)00149-x.; Mandeau A, Aries M-F, Bieber T. et al. Rhealba Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators. Planta Med. 2011:77(09);900–906. doi:10.1055/s-0030-1250649.; Stalder JF, Tennstedt D, Deleuran M, et al. Fragility of epidermis and its consequence in dermatology. J Eur Acad Dermatol Venereol. 2014;28(Suppl 4):1–18. doi:10.1111/jdv.12509.; Saint Aroman M, Guillot P, Dahan S, et al. Efficacy of a repair cream containing Rhealba oat plantlets extracts, L-ALA-L-GLU dipeptide, and hyaluronic acid in wound-healing following dermatological acts: a meta-analysis of >2,000 patients in eight countries corroborated by a dermatopediatric clinical case. Clin Cosmet Investig Dermatol. 2018;11:579–589. doi:10.2147/CCID.S177614.; Wollenberg A., Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32(Suppl 1):1–15. doi:10.1111/jdv.14846.; Grimalt R, Mengeaud V, Cambazard F. The Steroid-Sparing Effect of an Emollient Therapy in Infants with Atopic Dermatitis: A Randomized Controlled Study. Dermatology. 2006;214(1):61–67. doi:10.1159/000096915.; Patel N, Feldman SR. Adherence in Atopic Dermatitis. In: Management of Atopic Dermatitis. Fortson EA, Feldman SR, Strowd LC, eds. Springer; 2017. pp. 139–159. doi:10.1007/978-3-319-64804-0_12.; https://www.pedpharma.ru/jour/article/view/1885

Availability: https://www.pedpharma.ru/jour/article/view/1885
https://doi.org/10.15690/pf.v17i4.2160

Pharmacotherapy: Its impact on morphofunctional characteristics of the epidermal barrier ; Медикаментозная терапия с точки зрения влияния на морфофункциональные характеристики эпидермального барьера

Authors: Petrunin D.D.

Source: Vestnik dermatologii i venerologii; Vol 95, No 1 (2019); 59-76 ; Вестник дерматологии и венерологии; Vol 95, No 1 (2019); 59-76 ; 2313-6294 ; 0042-4609 ; 10.25208/0042-4609-2019-95-1

Subject Terms: epidermal barrier, epidermal lipids, corneodesmosomes, tight junctions, transepidermal water loss, эпидермальный барьер, эпидермальные липиды, корнеодесмосомы, плотные контакты, трансэпидермальная потеря воды

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/468/438; https://vestnikdv.ru/jour/article/view/468

Availability: https://vestnikdv.ru/jour/article/view/468
https://doi.org/10.25208/0042-4609-2019-95-1-59-76

THE ROLE OF EPIDERMAL BARRIER IMPAIRMENTS IN ATOPIC DERMATITIS: MODERN CONCEPTS OF DISEASE PATHOGENESIS ; РОЛЬ НАРУШЕНИЙ ЭПИДЕРМАЛЬНОГО БАРЬЕРА ПРИ АТОПИЧЕСКОМ ДЕРМАТИТЕ: СОВРЕМЕННЫЕ КОНЦЕПЦИИ ПАТОГЕНЕЗА ЗАБОЛЕВАНИЯ

Authors: Nikolay N. Murashkin, Eduard T. Ambarchian, Alexander I. Materikin, Roman V. Epishev, Н. Н. Мурашкин, Э. Т. Амбарчян, А. И. Материкин, Р. В. Епишев

Contributors: Zeldis-Pharma LLC, ООО ЗелдисФарма

Source: Current Pediatrics; Том 17, № 1 (2018); 85-88 ; Вопросы современной педиатрии; Том 17, № 1 (2018); 85-88 ; 1682-5535 ; 1682-5527

Subject Terms: микробиом, atopic dermatitis, epidermal barrier, microbiome, атопический дерматит, эпидермальный барьер

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/1869/769; Dinulos JG, Trickett A, Crudele C. New science and treatment paradigms for atopic dermatitis. Curr Opin Pediatr. 2018;30(1): 161–168. doi:10.1097/Mop.0000000000000560.; Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int. 2018;67(1):3–11. doi:10.1016/j.alit.2017.10.002.; Федеральные клинические рекомендации по оказанию медицинской помощи детям с атопическим дерматитом. — М.; 2016.; Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681–687. doi:10.1016/j.jaad.2016.05.028.; Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118–127. doi:10.1016/j.jaci.2003.09.033.; Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis — a prospective follow-up to 7 years of age. Allergy. 2000;55(3): 240–245. doi:10.1034/j.1398-9995.2000.00391.x.; Peroni DG, Piacentini GL, Bodini A, et al. Prevalence and risk factors for atopic dermatitis in preschool children. Br J Dermatol. 2008;158(3):539–543. doi:10.1111/j.1365-2133.2007.08344.x.; Wild CP. Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1847–1850. doi:10.1158/1055-9965.EPI-05-0456.; Burbank AJ, Sood AK, Kesic MJ, et al. Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol. 2017;140(1):1–12. doi:10.1016/j.jaci.2017.05.010.; Prince AL, Antony KM, Chu DM, Aagaard KM. The microbiome, parturition, and timing of birth: more questions than answers. J Reprod Immunol. 2014;104–105:12–19. doi:10.1016/j.jri.2014.03.006.; Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006;118(2):511–521. doi:10.1542/peds.2005-2824.; van Nimwegen FA, Penders J, Stobberingh EE, et al. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol. 2011;128(5):948–955. doi:10.1016/j.jaci.2011.07.027.; Penders J, Gerhold K, Stobberingh EE, et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol. 2013;132(3):601–607. doi:10.1016/j.jaci.2013.05.043.; Sordillo JE, Zhou YJ, McGeachie MJ, et al. Factors influencing the infant gut microbiome at age 3-6 months: findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART). J Allergy Clin Immunol. 2017;139(2):482–491. doi:10.1016/j.jaci.2016.08.045.; Guzik TJ, Bzowska M, Kasprowicz A, et al. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clin Exp Allergy. 2005;35(4):448–455. doi:10.1111/j.1365-2222.2005.02210.x.; Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9(4):244–253. doi:10.1038/nrmicro2537.; Mauro T, Grayson S, Gao WN, et al. Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch Dermatol Res. 1998;290(4):215–222. doi:10.1007/s004030050293.; Hachem JP, Man MQ, Crumrine D, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol. 2005; 125(3):510–520. doi:10.1111/j.0022-202X.2005.23838.x.; Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 2010; 125(1):16–29. doi:10.1016/j.jaci.2009.11.008.; Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi:10.1038/ng1767.; Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8): 1892–1908. doi:10.1038/jid.2009.133.; Barker JN, Palmer CN, Zhao YW, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127(3):564–567. doi:10.1038/sj.jid.5700587.; O’Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40(7):965–972. doi:10.1111/j.13652222.2010.03522.x.; Catherine Mack Correa M, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi:10.1155/2012/836931.; Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi:10.1016/j.jaci.2008.01.022.; Walley AJ, Chavanas S, Moffatt MF, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet. 2001;29(2):175–178. doi:10.1038/ng728.; Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823. doi:10.1016/j.jaci.2014.08.005.; Tiplica GS, Boralevi F, Konno P, et al. The regular use of an emollient improves symptoms of atopic dermatitis in children: a randomized controlled study. J Eur Acad Dermatol Venereol. Forthcoming 2018. doi:10.1111/jdv.14849.; Barba C, Alonso C, Marti M, et al. Skin barrier modification with organic solvents. Biochim Biophys Acta. 2016;1858(8):1935–1943. doi:10.1016/j.bbamem.2016.05.009.; Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78(1):27–30. doi:10.1080/00015559850135788.; Choi MJ, Maibach HI. Role of ceramides in barrier function of healthy and diseased skin. Am J Clin Dermatol. 2005;6(4):215–223. doi:10.2165/00128071-200506040-00002.; Breiden B, Gallala H, Doering T, Sandhoff K. Optimization of submerged keratinocyte cultures for the synthesis of barrier ceramides. Eur J Cell Biol. 2007;86(11–12):657–673. doi:10.1016/j.ejeb.2007.02.006.; Andreassi M, Forleo P, DiLorio A, et al. Efficacy of gammalinolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res. 1997;25(5):266–274. doi:10.1177/0300060597 02500504.; Amagai Y, Oida K, Matsuda A, et al. Dihomo-gamma-linolenic acid prevents the development of atopic dermatitis through prostaglandin D1 production in NC/Tnd mice. J Dermatol Sci. 2015;79(1): 30–37. doi:10.1016/j.jdermsci.2015.03.010.; Simon D, Eng PA, Borelli S, et al. Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis. Adv Ther. 2014;31(2):180–188. doi:10.1007/s12325-014-0093-0.; Desbois AP, Lawlor KC. Antibacterial activity of long-chain polyunsaturated fatty acids against Propionibacterium acnes and Staphylococcus aureus. Mar Drugs. 2013;11(11):4544–4557. doi:10.3390/md11114544.; Sergeant S, Rahbar E, Chilton FH. Gamma-linolenic acid, dihommo-gamma linolenic, eicosanoids and inflammatory processes. Eur J Pharmacol. 2016;785:77–86. doi:10.1016/j.ejphar. 2016.04.020.

Availability: https://vsp.spr-journal.ru/jour/article/view/1869
https://doi.org/10.15690/vsp.v17i1.1859

Contemporary View of the Structural and Functional Peculiarities of the Skin, Items of Care and Prevention of Dermatological Pathology in Infants ; Современные представления о структурно-функциональных особенностях кожи, правилах ухода и профилактике дерматологической патологии у детей первого года жизни

Authors: Nikolay N. Murashkin, Eduard Т. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Dmitriy V. Fedorov, Н. Н. Мурашкин, Э. Т. Амбарчян, Р. В. Епишев, А. И. Материкин, Д. В. Фёдоров

Contributors: Zeldis-Pharma LLC, OOO «Зелдис-Фарма»

Source: Current Pediatrics; Том 17, № 4 (2018); 341-345 ; Вопросы современной педиатрии; Том 17, № 4 (2018); 341-345 ; 1682-5535 ; 1682-5527

Subject Terms: экстракт хлопка, atopic dermatitis, diaper dermatitis, emollients, epidermal barrier, microbiome, cotton extract, атопический дерматит, пеленочный дерматит, эмоленты, эпидермальный барьер, микробиом

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/1933/818; Fluhr JW, Darlenski R, Lachmann N, et al. Infant epidermal skin physiology: adaptation after birth. Br J Dermatol. 2012;166(3): 483–490. doi:10.1111/j.1365-2133.2011.10659.x.; Fluhr JW, Darlenski R, Taieb A, et al. Functional skin adaptation in infancy — almost complete but not fully competent. Exp Dermatol. 2010;19(6):483–492. doi:10.1111/j.1600-0625.2009.01023.x.; Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol. 2008;128(7):1728–1736. doi:10.1038/sj.jid.5701239.; Stamatas GN, Nikolovski J, Luedtke MA, et al. Infant skin microstructure assessed in vivo differs from adult skin in organization and at the cellular level. Pediatr Dermatol. 2010;27(2):125–131. doi:10.1111/j.1525-1470.2009.00973.x.; Fluhr JW, Lachmann N, Baudouin C, et al. Development and organization of human stratum corneum after birth: electron microscopy isotropy score and immunocytochemical corneocyte labelling as epidermal maturation’s markers in infancy. Br J Dermatol. 2014;171(5):978–986. doi:10.1111/bjd.12880.; Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62(2):151–161. doi:10.2332/allergolint.13-RAI-0564.; Lund C. Issues in newborn skin care. Adv Neonatal Care. 2016;16(5):S1–S2. doi:10.1097/Anc.0000000000000346.; Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246. doi:10.1111/j.1600-065X.2011. 01027.x.; McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280–291. doi:10.1016/j.jaci.2012.12.668.; Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14): 1483–1494. doi:10.1056/NEJMra074081.; Ring J, Darsow U, Burgdorf WH, et al, editors. Braun-Falco Dermatologia. Lublin: Czelej; 2010. pp. 425–441.; Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015;45(3):566–574. doi:10.1111/cea.12495.; Pelc J, Czarnecka-Operacz M, Adamski Z. Structure and function of the epidermal barrier in patients with atopic dermatitis — treatment options. Part one. Postepy Dermatol Alergol. 2018;35(1):1–5. doi:10.5114/ada.2018.73159.; Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8): 1892–1908. doi:10.1038/jid.2009.133.; Fluhr JW, Behne MJ, Brown BE, et al. Stratum corneum acidification in neonatal skin: secretory phospholipase A2 and the sodium/ hydrogen antiporter-1 acidify neonatal rat stratum corneum. J Invest Dermatol. 2004;122(2):320–329. doi:10.1046/j.0022202X.2003.00204.x.; Ament W, Huizenga JR, Mook GA, et al. Lactate and ammonia concentration in blood and sweat during incremental cycle ergometer exercise. Int J Sports Med. 1997;18(1):35–39. doi:10.1055/s-2007-972592.; Thueson DO, Chan EK, Oechsli LM, Hahn GS. The roles of pH and concentration in lactic acid-induced stimulation of epidermal turnover. Dermatol Surg. 1998;24(6):641–645. doi:10.1111/j.1524-4725.1998.tb04221.x.; Eichenfield LF, Ellis CN, Mancini AJ, et al. Atopic dermatitis: epidemiology and pathogenesis update. Semin Cutan Med Surg. 2012;31(3 Suppl):S3–5. doi:10.1016/j.sder.2012.07.002.; Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: beyond filaggrin. An Bras Dermatol. 2016;91(4): 472–478. doi:10.1590/abd1806-4841.20164412.; Pelc J, Czarnecka-Operacz M, Adamski Z. The structure and function of the epidermal barrier in patients with atopic dermatitis — treatment options. Part two. Postepy Dermatol Alergol. 2018;35(2):123–127. doi:10.5114/ada.2018.75234.; Trzeciak M, Glen J, Rebala K, et al. Coexistence of 2282del4 FLG gene mutation and IL-18 -137G/C gene polymorphism enhances the risk of atopic dermatitis. Postepy Dermatol Alergol. 2016;33(1): 57–62. doi:10.5114/pdia.2015.48050.; Filipowska-Gronska A, Werynska-Kalemba M, Bozek A, et al. The frequency of polymorphic variants of filaggrin gene and clinical atopic dermatitis. Postepy Dermatol Alergol. 2016;33(1):37–41. doi:10.5114/pdia.2015.48036.; Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6): 1184–1190. doi:10.1016/j.jaci.2010.09.015.; Klunk C, Domingues E, Wiss K. An update on diaper dermatitis. Clin Dermatol. 2014;32(4):477–487. doi:10.1016/j.clindermatol.2014.02.003.; Охлопков В.А., Зубарева Е.Ю., Новиков Ю.А., и др. Оценка клинической эффективности топической комбинированной терапии больных экземой, осложненной бактериальной инфекцией // Вестник дерматологии и венерологии. — 2014. — № 3 — С. 121–127.

Availability: https://vsp.spr-journal.ru/jour/article/view/1933
https://doi.org/10.15690/vsp.v17i4.1929

Significance of the epidermal barrier and sensitisation to household allergens to the development of atopic march for primary prevention ; Значение эпидермального барьера и сенсибилизации к бытовым аллергенам на развитие атопического марша в обосновании первичной профилактики

Authors: E. Varlamov E., A. Pampura N., A. Asmanov N., Е. Варламов Е., А. Пампура Н., А. Асманов И.

Source: Bulletin of Siberian Medicine; Том 17, № 2 (2018); 114-120 ; Бюллетень сибирской медицины; Том 17, № 2 (2018); 114-120 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2018-17-2

Subject Terms: atopic march, epidermal barrier, sensitization, home dust mites, asthma, allergic rhinitis, prevention, атопический марш, эпидермальный барьер, сенсибилизация, клещи домашней пыли, бронхиальная астма, аллергический ринит, профилактика

File Description: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/1209/810; Dharmage S.C., Lowe A.J., Matheson M.C. et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014; 69 (1): 17–27. DOI:10.1111/all.12268.; Hill D.A., Spergel J.M. The atopic march. Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018; 120: 131–137. DOI:10.1016/j.anai.2017.10.037.; Pearce N., Aït-Khaled N., Beasley R. et al. ISAAC Phase Three Study Group. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007; 62: 758–766. DOI:10.1136/thx.2006.070169.; Bantz S.K., Zhu Z., Zheng T. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J. Clin. Cell. Immunol. 2014; 5 (2): 202. DOI:10.4172/2155-9899.1000202.; Strachan D.P., Butland B.K., Anderson H.R. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ. 1996; 312: 1195–1199. DOI:10.1136/bmj.312.7040.1195.; Tran M.M., Lefebvre D.L., Dharma C. et al. Canadian Healthy Infant Longitudinal Development Study investigators. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J. Allergy Clin. Immunol. 2018; 141 (2): 601–607. DOI:10.1016/j.jaci.2017.08.024.; Somanunt S., Chinratanapisit S., Pacharn P. et al. The natural history of atopic dermatitis and its association with Atopic March. Asian Pac. J. Allergy Immunol. 2017; 35 (3): 137–143. DOI:10.12932/AP0825.; Belgrave D.C., Granell R., Simpson A. et al. Developmental profiles of eczema, wheeze, and rhinitis: two populationbased birth cohort studies. PLoS Med. 2014; 11: e1001748. DOI.org/10.1371/journal.pmed.1001748.; Nemoto-Hasebe I., Akiyama M., Nomura T. et al. Clinical severity correlates with impaired barrier in filaggrinrelated eczema. Journal of Investigative Dermatology. 2009; 129 (3): 682–689. DOI:10.1038/jid.2008.280.; Elias P., Feingold K. Skin Barrier. New York; London, Informa Healthcare, 2005: 632.; Krien P., Kermici M. Evidence for the existence of a self-regulated enzymatic process within human stratum corneum-an unexpected role for urocanic acid. J. Invest Dermatol. 2000; 115 (3): 414–420. DOI:10.1046/j.1523- 1747.2000.00083.x.; Варламов Е.Е., Тагирова М.К., Комова Е.Г. и др. Клиническое значение мутаций гена FLG у детей с атопическим дерматитом. Российский вестник перинатологии и педиатрии. 2015; 2: 87–91. [Varlamov E.E., Tagirova M.K., Komova E.G. et al. Clinical significance of FLG gene mutations in children with atopic dermatitis. Rossiyskiy vestnik perinatologii i pediatrii – The Russian Bulletin of Perinatology and Pediatrics. 2015; 2: 87–91 (in Russ.)].; Ziyab A.H., Karmaus W., Zhang H. et al. Association of filaggrin variants with asthma and rhinitis: is eczema or allergic sensitization status an effect modifier? Int. Arch. Allergy Immunol. 2014; 164 (4): 308–318. DOI:10.1159/000365990.; Dębińska A., Danielewicz H., Drabik-Chamerska A. et al. Filaggrin loss-of-function mutations as a predictor for atopic eczema, allergic sensitization and eczema-associated asthma in Polish children population. Adv. Clin. Exp. Med. 2017; 26 (6): 991–998. DOI:10.17219/acem/61430.; Sala-Cunill A., Bartra J., Dalmau G. et al. Prevalence of asthma and severity of allergic rhinitis comparing 2 perennial allergens: house dust mites and parietaria judaica pollen. J. Investig. Allergol. Clin. Immunol. 2013; 23: 145–151.; Calderon M.A., Kleine-Tebbe J., Linneberg A. et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J. Allergy Clin. Immunol. 2015; 3: 843–855. DOI:10.1016/j.jaip.2015.06.019.; Sánchez-Borges M., Fernandez-Caldas E., Thomas W.R. et al. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organ. J. 2017; 10 (1): 14. DOI:10.1186/ s40413-017-0145-4.; Chapman M.D., Platts-Mills T.A. Purification and characterization of the major allergen from Dermatophagoides pteronyssinus-antigen P1. J. Immunol. 1980; 125: 587–592.; Roche N., Chinet T.C., Belouchi N. et al. Dermatophagoides pteronyssinus and bioelectric properties of airway epithelium: role of cysteine proteases. Eur. Respir. J. 2000; 16: 309–315.; Pichavant M., Charbonnier A., Taront S. et al. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J. Allergy Clin. Immunol. 2005; 115: 771–778. DOI:10.1016/j.jaci.2004.11.043.; Adam E., Hansen K.K., Astudillo O.F. et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J. Biol. Chem. 2006; 281: 6910–6923. DOI:10.1074/jbc.M507140200.; Halim T.Y.F., Steer C.A., Matha L. et al. Group 2 innate lymphoid cells are critical for the Initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014; 40: 425–435. DOI:10.1016/j.immuni.2014.01.011.; Ghaemmaghami A.M., Gough L., Sewell H.F. et al. Proteolytic activity of the major dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: allergen-induced Th2 bias determined at the dendritic cell level. Clin. Exp. Allergy. 2002; 32: 1468–1475. DOI:10.1046/j.1365-2745.2002.01504.x.; Schulz O., Sewell H.F., Shakib F. The interaction between the dust mite antigen Der p 1 and cell-signalling molecules in amplifying allergic disease. Clin. Exp. Allergy. 1999; 29: 439–444. DOI:10.1046/j.1365-2222.1999.00464.x.; Wan H., Winton H.L., Soeller C. et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin. Exp. Allergy. 2001; 31; 279–294. DOI:10.1046/j.1365-2222.2001.00970.x.; Brown S.J., Relton C.L., Liao H. et al. Filaggrin null mutations and childhood atopic eczema: A population-based case-control study. J. Allergy Clin. Immunol. 2008: 121: 940–946. DOI:10.1016/j.jaci.2008.01.013.; Flohr C., Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014; 69: 3–16. DOI:10.1111/all.12270.; Harris J.M., Williams H.C., White C. et al. Early allergen exposure and atopic eczema. Br. J. Dermatol. 2007; 156: 698–704. DOI:10.1111/j.1365-2133.2006.07710.x.; Arroyave W.D., Rabito F.A., Carlson J.C. et al. Impermeable dust mite covers in the primary and tertiary prevention of allergic disease: a meta-analysis. Arch. Dermatol. 2007; 143: 12: 1570–1577. DOI:10.1016/j. anai.2014.01.006.; Wilson J.M., Platts-Mills T.A.E. Home environmental interventions for house dust mite. J Allergy Clin. Immunol. Pract. 2018; 6(1): 1–7. DOI:10.1016/j.jaip.2017.10.003.; Lowe A.J., Leung D.Y.M., Tang M.L.K. et al. The skin as a target for prevention of the atopic march. Ann. Allergy Asthma Immunol. 2018; 120 (2): 145–151. DOI:10.1016/j.anai.2017.11.023.; Horimukai K., Morita K., Narita M. et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J. Allergy Clin. Immunol. 2014; 134 (4): 824–830. DOI:10.1016/j.jaci.2014.07.060.; Simpson E.L., Chalmers J.R., Hanifin J.M. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J. Allergy Clin. Immunol. 2014; 134: 818–823. DOI:10.1016/j.jaci.2014.08.005.; https://bulletin.tomsk.ru/jour/article/view/1209

Availability: https://bulletin.tomsk.ru/jour/article/view/1209
https://doi.org/10.20538/1682-0363-2018-2-114-120

ДИНАМИКА МОРФОФУНКЦИОНАЛЬНЫХ ПАРАМЕТРОВ КОЖИ ПРИ ХРОНИЧЕСКИХ ДЕРМАТОЗАХ НА ФОНЕ ИСПОЛЬЗОВАНИЯ ЭМОЛЕНТОВ

Authors: Кондратьева, Ю., Шепилева, Т., Ерошенко, Н.

Subject Terms: МОРФОФУНКЦИОНАЛЬНЫЕ ХАРАКТЕРИСТИКИ КОЖИ, ЭПИДЕРМАЛЬНЫЙ БАРЬЕР, ХРОНИЧЕСКИЕ ДЕРМАТОЗЫ, ЭМОЛЕНТЫ, КСЕРОЗ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/dinamika-morfofunktsionalnyh-parametrov-kozhi-pri-hronicheskih-dermatozah-na-fone-ispolzovaniya-emolentov
http://cyberleninka.ru/article_covers/15751584.png

МЕТОДЫ НЕИНВАЗИВНОЙ ОЦЕНКИ БАРЬЕРНЫХ СВОЙСТВ КОЖИ

Authors: Утц, С., Каракаева, А., Галкина, Е.

Subject Terms: НЕИНВАЗИВНЫЕ МЕТОДЫ ДИАГНОСТИКИ, ТРАНСЭПИДЕРМАЛЬНАЯ ПОТЕРЯ ВОДЫ., ЭПИДЕРМАЛЬНЫЙ БАРЬЕР

File Description: text/html

Availability: http://cyberleninka.ru/article/n/metody-neinvazivnoy-otsenki-bariernyh-svoystv-kozhi
http://cyberleninka.ru/article_covers/15705306.png

Efficacy of skin care products for acne patients ; Эффективность средств ухода за кожей у больных акне

Authors: Araviyskaya Y.R., Sokolovsky Y.V.

Source: Vestnik dermatologii i venerologii; Vol 89, No 2 (2013); 67-71 ; Вестник дерматологии и венерологии; Vol 89, No 2 (2013); 67-71 ; 2313-6294 ; 0042-4609

Subject Terms: acne, skin barrier properties, basic care, Cetaphil Dermacontrol, акне, эпидермальный барьер, Сетафил

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/572/502; https://vestnikdv.ru/jour/article/view/572

Availability: https://vestnikdv.ru/jour/article/view/572
https://doi.org/10.25208/vdv572

Corneal protectors in dermatology ; Корнеопротекторы в дерматологии

Authors: PERLAMUTROV Y.N., OLKHOVSKAYA K.B.

Source: Vestnik dermatologii i venerologii; Vol 88, No 5 (2012); 92-96 ; Вестник дерматологии и венерологии; Vol 88, No 5 (2012); 92-96 ; 2313-6294 ; 0042-4609

Subject Terms: epidermal barrier, corneobiology, corneotherapy, dermal and membrane structure, corneal protector, эпидермальный барьер, корнеобиология, корнеотерапия, дерма-мембранная структура, корнеопротектор

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/736/665; https://vestnikdv.ru/jour/article/view/736

Availability: https://vestnikdv.ru/jour/article/view/736
https://doi.org/10.25208/vdv736

ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПРЕПАРАТОВ КОСМЕТИЧЕСКОЙ ЛИНИИ «АЙСИДА» В ЛЕЧЕНИИ ДЕТЕЙ С АТОПИЧЕСКИМ ДЕРМАТИТОМ

Authors: Горланов, И., Леина, Л., Милявская, И., Куликова, С.

Subject Terms: АТОПИЧЕСКИЙ ДЕРМАТИТ, ЭПИДЕРМАЛЬНЫЙ БАРЬЕР, КАЧЕСТВО ЖИЗНИ, ЛИПОСОМАЛЬНАЯ КОСМЕТИКА "АЙСИДА"

File Description: text/html

Availability: http://cyberleninka.ru/article/n/effektivnost-i-bezopasnost-preparatov-kosmeticheskoy-linii-aysida-v-lechenii-detey-s-atopicheskim-dermatitom
http://cyberleninka.ru/article_covers/15790355.png

Advanced moisturizing products for the sensitive skin therapy ; Современные увлажняющие средства ухода за чувствительнойкожей

Authors: Pashinyan A.G., Gordienko E.S., Dzhavaeva D.G., Shakhnovich A.A., Gordiyenko Y.S., Dzhavayeva D.G., Shahnovich A.A.

Source: Vestnik dermatologii i venerologii; Vol 87, No 3 (2011); 138-140 ; Вестник дерматологии и венерологии; Vol 87, No 3 (2011); 138-140 ; 2313-6294 ; 0042-4609

Subject Terms: external softening and moisturizing drugs, epidermal barrier, наружные смягчающие и увлажняющие средства, эпидермальный барьер

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/1042/971; https://vestnikdv.ru/jour/article/view/1042

Availability: https://vestnikdv.ru/jour/article/view/1042
https://doi.org/10.25208/vdv1042

Experience of using peroral cosmetic products from the Emolium series in the complex therapy of children suffering from atopic dermatitis ; Опыт применения наружных средств косметической линии Эмолиум в комплексной терапии детей, больных атопическим дерматитом

Authors: TEKUCHEVA L.V., ZNAMENSKAYA L.F.

Source: Vestnik dermatologii i venerologii; Vol 87, No 2 (2011); 71-77 ; Вестник дерматологии и венерологии; Vol 87, No 2 (2011); 71-77 ; 2313-6294 ; 0042-4609

Subject Terms: atopic dermatitis, epidermal barrier, emollients, Emolium cosmetic products, transepidermal water loss, атопический дерматит, эпидермальный барьер, эмоленты, косметические средства Эмолиум, трансэпидермальная потеря воды

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/1003/932; https://vestnikdv.ru/jour/article/view/1003

Availability: https://vestnikdv.ru/jour/article/view/1003
https://doi.org/10.25208/vdv1003

Efficient application of external softening and moisturizingdrugs for the treatment of atopic dermatitis in children ; Об эффективности применения наружных смягчающихи увлажняющих средств в терапии атопическогодерматита у детей

Authors: Proshutinskaya D.V., Tekucheva L.V.

Source: Vestnik dermatologii i venerologii; Vol 86, No 6 (2010); 115-123 ; Вестник дерматологии и венерологии; Vol 86, No 6 (2010); 115-123 ; 2313-6294 ; 0042-4609

Subject Terms: atopic dermatitis, Locobase Repair cream, Atoderm cream, epidermal barrier, tewametry, corneometry, pH-metry, атопический дерматит, крем Локобейз Рипеа, крем Атодерм®, эпидермальный барьер, теваметрия, корнеометрия, рН-метрия

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/853/782; https://vestnikdv.ru/jour/article/view/853

Availability: https://vestnikdv.ru/jour/article/view/853
https://doi.org/10.25208/vdv853